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ABSTRACT
The identiﬁcation and grading of adverse events (AEs)
during the conduct of clinical trials is a labor-intensive
and error-prone process. This paper describes and
evaluates a software tool developed by City of Hope to
automate complex algorithms to assess laboratory
results and identify and grade AEs. We compared AEs
identiﬁed by the automated system with those previously
assessed manually, to evaluate missed/misgraded AEs.
We also conducted a prospective paired time
assessment of automated versus manual AE
assessment. We found a substantial improvement in
accuracy/completeness with the automated grading tool,
which identiﬁed an additional 17% of severe grade 3e4
AEs that had been missed/misgraded manually. The
automated system also provided an average time saving
of 5.5 min per treatment course. With 400 ongoing
treatment trials at City of Hope and an average of 1800
laboratory results requiring assessment per study, the
implications of these ﬁndings for patient safety are
enormous.
INTRODUCTION
Patient safety is of major concern during the
conduct of clinical trials, where experimental and
potentially toxic therapies are evaluated in
humans.
1 Complete adverse event (AE) reporting
during trial conduct imposes a large burden and
presents a major challenge, requiring multiple
assessments over time, for every treatment course
for each participant.
2e4 Chart review to assess the
presence and severity of AEs is expensive, inefﬁcient,
and imperfect.
56Problems include under-reporting
of low grade/recurrent AEs, and inconsistent or
incomplete characterization and reporting of
high grade AEs.
7 Without accurate AE reporting,
treatments may appear less toxic than they are,
potentially endangering patients.
8
Approximately 30% of more than 100000 clinical
trials registered on the http://ClinicalTrials.gov/
website involve cancer. To assess AEs in oncology,
the National Cancer Institute (NCI) developed the
Common Terminology Criteria for Adverse Events
(CTCAE),
8 9 a graduated scale for evaluating the
severity of w350 qualitative and quantitative AEs,
from grade ‘1’ (least severe) to ‘4’ (most severe),
with grade ‘5’ signifying AE-related death. Approx-
imately 13% of the CTCAE is based on laboratory
results, accounting for a signiﬁcant number of
reportable AEs (see ﬁgure 1 for examples).
This critical need to accurately and efﬁciently
assess large quantities of laboratory-based AEs
provides a prime opportunity to apply automated
decision support to reduce errors in transcription,
calculation, and interpretation. However, to date
development of such applications is lagging due to
barriers such as organizational issues, inadequate
design, poor system performance, non-standard
terminology/clinical documentation, and lack of
demonstrable system value.
10e13 As Bates et al
state, ‘information technology has been viewed as
a commodity, like plumbing, rather than as a stra-
tegic resource that is vitally important to the
delivery of care.’
14 Herein we report on a strategic
decision support tool developed at City of Hope
(COH) to improve subject safety, and our evalua-
tion of this tool’s utility and value.
As a NCI-funded Comprehensive Cancer Center,
COH conducts w400 clinical trials each year,
enrolling over 1500 patients annually. Recognizing
the enormous safety challenges created by this
volume, in 2005 the COH Department of Infor-
mation Sciences developed a software tool to
automate detection of laboratory-based AEs. This
decision support tool instantaneously assesses
hundreds of electronic laboratory results to detect
any abnormal ﬁndings, and grades AE severity
according to CTCAE algorithms. While detecting
abnormal laboratory results has been an infor-
matics staple for many years,
15e17 applying deci-
sion support to invoke the complex CTCAE
algorithms to automatically grade AEs represents
a novel application.
COH Clinical Research Associates (CRAs) have
assessed over 1 million laboratory results using our
automated grading tool to date. Recognizing the
potential value to other institutions, COH devel-
oped an open source version, the Cancer Auto-
mated Lab-based Adverse Event Grading Service
(CALAEGS). While experientially we believed this
tool greatly enhanced the validity and efﬁciency of
laboratory-based AE grading, a formal evaluation
was required to conﬁrm this impression. This paper
describes our evaluation of CALAEGS, to our
knowledge the ﬁrst open source tool to assist with
the complex task of grading laboratory data to
ensure patient safety.
METHODS
CALAEGS intakes electronic laboratory data, and
provides grading results through a web-based user
interface, web services, and/or a Java API (applica-
tion programming interface). The user interface
allows institutions to customize the system to
their speciﬁc data source formats and coding. The
system is installed behind an institution’s ﬁrewall
to avoid conﬁdentiality issues. Laboratory data can
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Brief communicationbe submitted as comma-separated values, Extensible Markup
Language (XML), or Health Level Seven (HL7) version 3
messages. Grading results are returned in a machine readable
format compatible with the original input format, and as
a human-consumable ﬂowsheet rendered via Portable Document
Format (PDF) (see ﬁgure 2).
CALAEGS incorporates national standards such as the
Biomedical Research Information Domain Group (BRIDG)
model
18 and Uniﬁed Code for Units of Measure (UCUM),
19 and
is certiﬁed as bronze-level compatible with NCI’s Cancer
Biomedical Informatics Grid (caBIG
R).
20 It runs on Java 1.5+ in
a J2EE web container (Tomcat 5.0+ and JBoss 4.0.5+) and
requires a MySQL 5.0+ database.
CALAEGS assesses 39 laboratory-based AE terms based on
NCI CTCAE version 3.0
9 (refer to table 2). The grading algo-
rithms received thorough testing across several phases, including
unit, integration, system, and regression testing. The test
approach included a range of conditions, including grade
boundaries, simple and complex assessments, and fail condi-
tions. CALAEGS assessments are considered preliminary only, as
Figure 1 Example of laboratory-based adverse event (AE) grading algorithms for two CTCAE V.3.0 organ systems: blood/bone marrow and
metabolic/laboratory. LLN, lower limit of normal; ULN, upper limit of normal; WBC, white blood cell.
Figure 2 CALAEGS screenshots showing the entry screen for assessing a single laboratory result, for example, from an outside laboratory with no
electronic ﬁle available (left), and the ﬂowsheet generated to grade multiple laboratory-based adverse events (AEs) imported from an electronic ﬁle
(right). CALAEGS, Cancer Automated Lab-based Adverse Event Grading Service.
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Brief communicationsome laboratory-based AE grades depend on human judgment as
well, such as knowledge of additional patient conditions (eg,
concomitant life-threatening consequences).
In a paired retrospective study design, we compared the
accuracy and completeness of AE data graded manually, prior to
the availability of the automated tool, with results reassessed via
CALAEGS. We evaluated 10 sequential in-house therapeutic trials
of varying size, diagnoses, and phase, from the time frame just
prior to implementing our automated grading service, to mini-
mize confounding factors (eg, CRA expertise). These 10 trials
encompassed 40 patients and 18603 laboratory results (table 1).
The 18603 laboratory results were read into CALAEGS, and
the automated results compared with manually graded results
recorded in our clinical trials system. Discrepancies were cate-
gorized as missed AEs (true AEs that were not identiﬁed) or
misgraded AEs (AEs with an incorrect numeric grade or direc-
tion, ie, hypo- vs hyper-). All discordant results were reviewed
by our QA experts to verify that each suspected discrepancy was
a true error, eliminating any protocol-speciﬁc exceptions (eg, if
the study only requires recording the highest grade per course.)
To quantify AE grading efﬁciency, we conducted a prospective
paired evaluation comparing time required for manual versus
automated AE grading. In timed sessions, four CRAs graded ﬁve
patients each from their current protocol portfolio, ﬁrst manually
and then 2e4 weeks later utilizing the CALAEGS tool, yielding
20 paired assessments. The assessment sequence was ﬁxed
(manual followed by automated), as if CALAEGS was run ﬁrst,
familiarity with the resulting AEs might have increased CRA
efﬁciency when re-grading AEs manually.
A protocol specifying the design and regulatory processes for
this evaluation was approved by the COH Institutional Review
Board. The protocol stipulated that the Principal Investigator
and biostatistician for studies evaluated were to be notiﬁed of
any grading discrepancies identiﬁed; if any serious consequences
were identiﬁed, the IRB and appropriate regulatory agencies
would be notiﬁed as well. Analyses were conducted using SAS
software version 9.1 (SAS Institute).
RESULTS
From the 18603 laboratory results, 643 true AEs were detected.
No valid AEs identiﬁed manually were missed by the automated
system, and review of all 643 AEs by our QA experts veriﬁed
that the CALAEGS grades were accurate. Therefore, discrep-
ancies between the automated and manual approaches were
attributable to errors made during manual grading, found to be
inaccurate 15% of the time (96/643, table 2). Seventy laboratory-
based AEs (11%) were missed by manual grading, and 26
manually graded AEs (4%) were misgraded (25 understated the
condition, one was in the wrong direction).
Of the missed AEs, 86% (60/70) were relatively minor (grade
1e2). However, 22 severe AEs (grade 3e4) missed detection by
the manual method, through lack of identiﬁcation (n¼10) or
incorrect grading to a lower level (n¼12). Out of 130 severe
grade 3e4 AEs identiﬁed via CALAEGS, 17% were missed/
misgraded manually. Overall, 40% of patients evaluated (16)
experienced one or more missed/misgraded severe AEs.
Figure 3 shows the direction and magnitude of grading error
for 101 missed/misgraded AEs. The majority involved under-
reporting; however, in ﬁve instances the manually recorded AE
grade was higher than the true result (recorded as grade 1, true
grade 0). One misgraded AE (see ‘*’ in ﬁgure 3) was recorded at
the appropriate grade, however the direction was incorrect
(‘hyper’ when it was actually ‘hypo’).
Table 1 Protocols for comparing manual versus automated laboratory-
based adverse event (AE) grading
Study number Study phase
Number of COH
patients graded
Number of laboratory
results evaluated
Hematologic protocols
1 Pilot 8 9775
2 Pilot 5 5117
3 I/II 1 614
Subtotal 14 15506
Solid tumor protocols
4 I 13 1382
5 I 3 379
6 I 1 313
7 I 2 150
8I 2 6 5
9 II 4 542
10 II 1 266
Subtotal 26 3097
Total 40 18603
COH, City of Hope.
Table 2 Comparison of laboratory-based adverse events (AEs)
detected by manual versus automated grading method by AE term for
643 true AEs*
AE term
True
AEs
AEs correctly
detected
manually
AEs missed
by manual
method
AEs
misgraded
manually
Hematologic laboratory results
Hemoglobin 47 43 2 2
Leukocytes 47 40 5 2
Neutrophils 29 22 6 1
Platelets 48 46 1 1
PTT* 6 5 1 0
Subtotal 177 156 15 6
Chemistry laboratory results
Acidosis/alkalosis 5 5 0 0
Alkaline phosphatase 28 26 1 1
ALT* 38 34 1 3
Amylase 1 1 0 0
AST* 58 52 3 3
Bicarbonate serum low 14 10 4 0
Bilirubin 7 6 1 0
Cholesterol 13 10 2 1
Creatine phosphokinase 2 2 0 0
Creatinine 21 19 2 0
GGT* 5 4 1 0
Hypoalbuminemia 39 35 4 0
Hyper/hypocalcemia 44 38 5 1
Hyper/hypoglycemia 40 30 7 3
Hyper/hypokalemia 29 24 3 2
Hyper/hypomagnesemia 34 26 6 2
Hyper/hyponatremia 26 24 2 0
Hypertriglyceridemia 17 14 3 0
Hyperuricemia 7 3 3 1
Hypophosphatemia 32 24 5 3
Lipase 2 2 0 0
Proteinuria 4 2 2 0
Subtotal 466 391 55 20
Total 643 547 70 26
Percent 85 11 4
This table shows the true AEs that were missed, misgraded, or correct; 5 labs that were
incorrectly graded manually as an AE, but the true Grade was 0, are not included here.
ALT, serum glutamic-pyruvic transaminase; AST, serum glutamic-oxaloacetic transaminase;
GGT, gamma glutamyl transferase; PTT, activated partial thromboplastin time.
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Brief communicationThe prospective timed grading evaluation showed that using
CALAEGS led to time savings in 18/20 paired assessments (90%);
the average time saved was 5 min 25 s (5:25) per treatment
course (95% CI 2:24 to 8:26). For two assessments the decision
support tool required slightly more time (10 s and 2 min).
DISCUSSION
Health information exchange systems can substantially impact
medical quality and safety through automated decision making
and knowledge acquisition tools.
21 Yet to date the nation’s
healthcare system has fallen far short in applying new tech-
nology safely and appropriately to enhance the translation of
new biomedical discoveries into practice.
11 Strategies for AE
detection that incorporate electronically screened data can cost
signiﬁcantly less per AE detected, an attractive improvement
over pure manual review.
22
The high prevalence of AEs has made patient safety a major
concern when treating patients with experimental clinical trial
agents.
11 Identiﬁcation of AEs is a major challenge, and effective
methods for detecting such events are required.
62 3Because
laboratory data are computerized, AEs detected through elec-
tronic surveillance of laboratory results and their normal ranges
are particularly suited for automated decision support.
24
A very high overall accuracy level was seen in our evaluation
(18502 correct assessments, 99.5%). Yet the fact remains that
17% of all severe grade 3e4 AEs went undetected by traditional
chart review, affecting 40% of patients evaluated. Fortunately,
a thorough review of the medical records of these 16 patients
showed that no harm occurred, as in each case concurrent
medical problems led to appropriate care. However, the potential
for patient harm certainly exists if severe AEs go undetected.
Missed/misgraded AEs are concerning not only for patient
safety, but for overall scientiﬁc validity. In phase I studies, dose
escalation is driven by AEs, such that discrepancies can impact
study conduct. Comprehensive AE reporting is needed to
correctly interpret trial results, and avoid under-representing
toxicity burden. Even low grade AE detection is crucial in
reporting clinical trials,
1 6 for example, to uncover pharmacoge-
netic syndromes. While 78% of errors in our evaluation involved
grade 1e2 AEs, even these reveal critical toxicity patterns prior to
introducing experimental agents into standard care.
Although the time savings was less dramatic than we
expected (w5.5 min per treatment course), even this small
improvement translates into a potentially large beneﬁt, given
the volume of laboratory results per protocol (averaging 1800 per
study in our evaluation). With an average of three courses of
treatment for 1500 patients accrued annually at COH, even
modest efﬁciency improvements have major impact.
Limitations and future plans
Due to the large number of laboratory results evaluated, it was
not possible to directly assess every result for true AEs that might
have been missed by both the manual and automated methods.
However, we can reasonably infer that such false negatives are
highly unlikely based on the testing and validation of the system.
Achieving the optimal speciﬁcity of detection systems often
still requires some manual review, prompted by the automated
decision support.
6 CALAEGS prompts such a review when
additional criteria are required to determine grade (eg, concurrent
hospitalization or physiological consequences). Therefore
CALAEGS is an aid to, not a replacement of, human judgment.
As with any decision support system, there is a potential
danger when changes to the input data or algorithms occur,
intentionally or unintentionally. Our domain experts are
continually vigilant for any changes in laboratory reporting
standards, and rigorous retesting/validation is performed if the
algorithms are updated. Recently NCI released CTCAE V.4.0,
with many more laboratory-based AEs involving qualitative
criteria. Integration of additional data sources regarding
patient status is optimal with the advent of CTCAE V.4.0,
planned for our next system enhancements. The caBIG
program is developing tools to manage AE collection and
regulatory/institutional reporting requirements (eg, caAERS);
integration of CALAEGS with such tools may facilitate accu-
rate real-time identiﬁcation of serious AEs that require imme-
diate reporting.
Information technology can not only help detect AEs, but also
facilitate more rapid response once an AE occurs.
11 Currently,
the COH grading system is used as a data collection tool
following treatment course completion. We are in the process of
deploying the system to conduct nightly surveillance of the past
day’s laboratory results, to provide caregivers with reﬁned
signals indicating worsening patient conditions. Deployment
will require an appropriate workﬂow in clinic, and avoidance of
‘alert fatigue’ among caregivers.
25 26 Adding a conﬁgurable rules
engine interface to incorporate protocol-speciﬁc rules to ‘ﬁne
tune’ the algorithms will provide additional efﬁciency in future.
Conclusions
Our evaluation demonstrated that CALAEGS improves accuracy,
completeness, and efﬁciency in detecting and grading laboratory-
based AEs, facilitating documentation of the full toxicity proﬁle
of experimental agents. With the large number of clinical trials
performed at centers nationwide, the potential beneﬁcial impact
on patient safety, efﬁcient resource usage, and unbiased trial
reporting is tremendous.
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Figure 3 Missed/misgraded adverse events (AEs) by the manual
assessment method, against the true grade as detected by CALAEGS;
dashed boxes highlight the severe (grade 3, 4) missed/misgraded AEs.
*Misgraded because of wrong direction: term incorrectly identiﬁed as
‘hyper’ instead of ‘hypo’. CALAEGS, Cancer Automated Lab-based
Adverse Event Grading Service.
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